🇺🇸 carbidopa-levodopa (Sinemet) in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Constipation — 2 reports (14.29%)
  2. Depression — 2 reports (14.29%)
  3. Diarrhoea — 2 reports (14.29%)
  4. Fall — 2 reports (14.29%)
  5. Abnormal Behaviour — 1 report (7.14%)
  6. Acute Kidney Injury — 1 report (7.14%)
  7. Adverse Drug Reaction — 1 report (7.14%)
  8. Adverse Reaction — 1 report (7.14%)
  9. Anaemia — 1 report (7.14%)
  10. Aortic Valve Disease — 1 report (7.14%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is carbidopa-levodopa (Sinemet) approved in United States?

carbidopa-levodopa (Sinemet) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for carbidopa-levodopa (Sinemet) in United States?

Baylor College of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.